What type of study is this?

September 17, 2025Frontiers in ImmunologyOpen Access

Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy

View Full Paper

Ask AI

Bookmark

Authors

Single-center analysis reports 72.7% overall response rate in relapsed/refractory multiple myeloma, suggesting durable responses.

BCMA CAR-T-cell therapy shows a 72.7% overall response rate (8/11) in relapsed/refractory multiple myeloma patients.
With a median follow-up of 23 months, 75% of responders remained relapse-free, while 50% were alive at data cutoff.
This observational analysis assessed patient outcomes following BCMA-targeted CAR-T-cell therapy in a clinical setting.
The findings highlight the therapy's safety and efficacy, with moderate cytokine release syndrome observed in most patients.

Hao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark